Phys Vivas · rheumatological
Antiphospholipid Syndrome — Viva Defence
DCE viva defence for Antiphospholipid Syndrome.
On this page & tools
Target exams
Antiphospholipid Syndrome Viva
Long Case Viva Defence
Opening statement
"This patient presents with a problem best framed as Antiphospholipid Syndrome. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]
Examiner questions
Q1: "What makes this urgent?" [1]
"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]
Q2: "What is your first investigation package?" [2]
"I order tests that change management now, not a scattergun panel." [1] [2]
Q3: "Walk me through treatment." [1]
"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]
Q4: "What is the classic trap?" [2]
"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]
Short case
Counsel the patient on the plan, risks and warning symptoms in plain language. [1] [2]
References
- [1]Vrotniakaite-Bajerciene K, Wang TF, Sabri E, Shorr R, et al. Recurrent VTE in patients with thrombophilia after stopping anticoagulation - A systematic review and meta-analysis Blood Adv, 2026.PMID 42448302
- [2]Fang HS, Zhang XY, Liu XY, Chen HD, et al. Chromogenic factor X-guided warfarin monitoring in lupus anticoagulant-positive primary antiphospholipid syndrome with adrenal hemorrhage and progressive deep vein thrombosis: a case report J Med Case Rep, 2026.PMID 42437947
- [3]Mohammadi A, Fattahi V Anesthesia in systemic lupus erythematosus: a review of key considerations and surgical challenges Perioper Med (Lond), 2026.PMID 42421133
- [4]Esteban-Sampedro J, Martín-Portugués M, Ruiz-Irastorza G, Mellor-Pita S, et al. Impact of systemic autoimmune diseases in maternal, fetal and neonatal outcomes in Spain Rheumatology (Oxford), 2026.PMID 42421209
- [5]Hidaka A, Kaneshige R, Nakamura S, Motoki Y, et al. Preliminary Evaluation of a Novel Lupus Anticoagulant Activity Assay Unaffected by Anticoagulants J Clin Lab Anal, 2026.PMID 42310902
- [6]Ordieres-Ortega L, Galeano-Valle F, López-Rubio M, Alonso-Beato R, et al. Recurrent VTE During Anticoagulation: Diagnosis, Systematic Evaluation, and Management Chest, 2026.PMID 42264028
- [7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
- [8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922